Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
Shihan Zhou, Ru Yao, Mengqi Zhang, Mingxia Jiang, Jiaxuan Liu, Mingxiao Li, Fei Ma, Bo Pan, Qiao Li · 2026
Read Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study by Shihan Zhou, Ru Yao, Mengqi Zhang, Mingxia Jiang, Jiaxuan Liu, Mingxiao Li, Fei Ma, Bo Pan, Qiao Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156173.txt.
Description
Breast cancer that feeds on hormones often resists the first round of drugs that block cell growth. Shihan Zhou and co-authors look at a second use of one such drug, dalpiciclib, in a 2026 study. Their patients had advanced cancer that grew again after a first drug of the same class.
The records came from 58 patients treated at several centers. Paired with hormone therapy, the drug held the cancer back for a median of 6.3 months. Gains ran longer when the drug came right after the first of its class failed. Low white cell counts were the main side effect, and no one stopped care for harm. The team calls the pair a workable later option.
Catalog record
| CREATOR | Shihan Zhou, Ru Yao, Mengqi Zhang, Mingxia Jiang, Jiaxuan Liu, Mingxiao Li, Fei Ma, Bo Pan, Qiao Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |